VRTX Vertex Pharmaceuticals: Company Short-Term Debts

Public company logo of Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals maintains absolute loyalty among cystic fibrosis patients, expanding its reach through pediatric therapies. Its monopoly in treating orphan diseases allows the company to exercise significant pricing power, setting high costs for treatment courses against minimal production expenses. However, geopolitical instability and sanctions create risks for component supplies. Short-term financial liabilities reflect loan repayment dynamics, where the indicator remains around 0.08.

VRTX (Vertex) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

Metric breakdowns and analytics for Vertex Corp (VRTX)

- stock price and consensus target price:
Stock Price Vertex|VRTX - Consensus Target
- company stock capitalization data:
Market Capitalization Vertex|VRTX - Company Buyout Price
- business book valuation details:
Book Value per Share Vertex Pharmaceuticals|VRTX - Book Capitalization|Market Value to Book Value Ratio vrtx.com|VRTX - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Vertex Pharmaceuticals|VRTX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Vertex Pharmaceuticals|VRTX - Company Aggregate Indebtedness|Debts to Book Capitalization Vertex|VRTX - Long-Term Debt|Company Short-Term Debts Vertex Pharmaceuticals|Quick Liquidity Indicator vrtx.com
- net income and valuation multiples indicators:
VRTX - Final Profit
Summary company analysis:Vertex (VRTX)
Manufactured products of vrtx.com

For Vertex Pharmaceuticals (VRTX), the short-term debt burden reflects the volume of obligations maturing within one year. This metric aggregates current loans and notes to determine the issuer's immediate liquidity. Low values confirm financial stability given the company's monopoly position in cystic fibrosis therapy. A stable cash flow from critical drugs minimizes refinancing risks, while sharp fluctuations on the chart signal a shift in capital management strategy.

Main competitors

Alnylam - Company Short-Term Debts|Insmed Inc. (INSM) - Company Current Liabilities|UTHR: Company Short-Term Debts|BMRN - Short-Term Debt Volume|BBIO (BridgeBio Pharma, Inc.) - Company Short-Term Debts|Company Short-Term Debts BGM Group Corp|Company Short-Term Debt Cogent Biosciences, Inc. (COGT)|Company Short-Term Debt XERS (Xeris Biopharma Holdings, Inc.)|Company Short-Term Debts KROS (Keros Pharma)|Short-Term Debt Volume Arcturus Corp (ARCT)|ETON: Company Current Liabilities|Current Liabilities KMDA|FULC: Company Short-Term Debts|Short-Term Debt Abeona Therapeutics Inc. (ABEO)|MREO (Mereo BioPharma Group) - Company Short-Term Debts|Company Short-Term Indebtedness PLX (Protalix BioTherapeutics, Inc)|Company Current Liabilities PLRX (Pliant Therapeutics)|APLT (Applied Therapeutics Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Rein Therapeutics RNTX|GELS (Gelteq Ltd) - Current Liabilities|Aytu Therapeutics - Company Short-Term Debts|Company Short-Term Loans and Borrowings CMMB (Chemomab Therapeutics)|SRXH: Company Short-Term Debts|Polyrizon (PLRZ) - Company Short-Term Debts|Company Short-Term Debt Aeterna Zentaris Inc|CYTH: Company Short-Term Loans and Borrowings|Company Short-Term Debt Inozyme Pharma, Inc. (INZY)|Company Current Liabilities Reneo Pharmaceuticals, Inc RPHM|Company Short-Term Debts CSCI (COSCIENS Biopharma Inc.)